2-[4-(Benzenesulfonyl)piperazin-1-yl]-1,3-benzothiazole

Catalog No. :
ACSYHC932
CAS No. :
309268-43-7
Molecular Formula :
C17H17N3O2S2
Molecular Weight :
359.48

IUPAC Name:2-(4-(phenylsulfonyl)piperazin-1-yl)benzo[d]thiazole

2-[4-(Benzenesulfonyl)piperazin-1-yl]-1,3-benzothiazole structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g90%$565.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-[4-(Benzenesulfonyl)piperazin-1-yl]-1,3-benzothiazole
IUPAC Name2-(4-(phenylsulfonyl)piperazin-1-yl)benzo[d]thiazole
MDL No.MFCD01626225
Molecular FormulaC17H17N3O2S2
Molecular Weight359.48
SMILESO=S(N1CCN(C2=NC3=CC=CC=C3S2)CC1)(C4=CC=CC=C4)=O
InChI KeyVFJZPUKXXPGRNK-UHFFFAOYSA-N
Synonym2-[4-(PHENYLSULFONYL)PIPERAZINO]-1,3-BENZOTHIAZOLE;2-[4-(benzenesulfonyl)piperazin-1-yl]-1,3-benzothiazole;2-(4-(Phenylsulfonyl)piperazin-1-yl)benzo[d]thiazole;Benzothiazole, 2-[4-(phenylsulfonyl)-1-piperazinyl]-
CAS No.309268-43-7

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACSYHC932 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACIBGE162 route compound structure diagram
    ACIBGE16255745-83-0 In Stock
  4. Then
  5. ACSYHC932 route product structure diagram
    ACSYHC932309268-43-7
Inquiry

2. ACSYHC932 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACIRBE834 route compound structure diagram
    ACIRBE83419402-64-3 In Stock
  2. Plus
  3. ACIBGE162 route compound structure diagram
    ACIBGE16255745-83-0 In Stock
  4. Then
  5. ACSYHC932 route product structure diagram
    ACSYHC932309268-43-7
Inquiry

Comments (0)